

TRADEMARK ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Credit Suisse AG		01/31/2011	bank: SWITZERLAND
RECEIVING PARTY DATA			
Name:	King Pharmaceuticals Research and Development, Inc.		
Street Address:	4000 Centre Green Way		
City:	Cary		
State/Country:	NORTH CAROLINA		
Postal Code:	27513		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 34			
Property Type	Number	Word Mark	
Registration Number:	1473847	ADENOCARD	
Registration Number:	1816335	ADENOSCAN	
Registration Number:	1541189	ADENOSCAN	
Registration Number:	1812659	ALTACE	
Registration Number:	2669786	AVINZA	
Registration Number:	3319329	AVINZA	
Registration Number:	1040408	CORGARD	
Registration Number:	1170890	CORZIDE	
Registration Number:	2167335	CYTOMEL	
Registration Number:	3049183	DP	
Registration Number:	1742709	DP	
Registration Number:	1810413		
Registration Number:	2016089	LEVOXYL	
Registration Number:	2158841		

900182913

TRADEMARK
REEL: 004465 FRAME: 0696

CH \$865.00 1473847

Registration Number:	1657982	LIQUI-CHAR
Registration Number:	0874778	PULMONAIRE
Registration Number:	3362798	REMOXY
Registration Number:	0926416	SILVADENE
Registration Number:	1020307	SILVADENE
Registration Number:	0715343	SKELAXIN
Registration Number:	2168566	SONATA
Registration Number:	1772760	SYNERCID
Registration Number:	2396275	SYNERCID
Registration Number:	1652129	THEREVAC
Registration Number:	2044605	THROMBIN-JMI
Registration Number:	3550781	THROMBI-PAD
Registration Number:	1393762	TUSSIGON
Serial Number:	77253473	KING ON DEMAND
Serial Number:	85057044	OPTIMAL OPIOID PHARMACOTHERAPY IN INDIVIDUALIZED MULTIMODAL ANALGESIA
Serial Number:	77945568	PAIN WATCH
Serial Number:	77945569	PAIN WATCH
Serial Number:	77612033	REMOXY (OXYCODONE CONTROLLED-RELEASE) CAPSULES
Serial Number:	77612057	REMOXY XRT (OXYCODONE CONTROLLED-RELEASE) CAPSULES EXTRACTION RESISTANT TECHNOLOGY
Serial Number:	77103099	THROMBI-PASTE

CORRESPONDENCE DATA

Fax Number: (202)778-5299

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 202.662.5299

Email: trademarks@cov.com

Correspondent Name: Kathleen T. Gallagher-Duff, Esq.

Address Line 1: 1201 Pennsylvania Avenue, N.W.

Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:	029459.00030
NAME OF SUBMITTER:	Cheryl L. Fountain/Paralegal Specialist
Signature:	/cherylfountain/
Date:	02/02/2011

Total Attachments: 4

source=King R&D TM Release#page1.tif

source=King R&D TM Release#page2.tif

source=King R&D TM Release#page3.tif

source=King R&D TM Release#page4.tif

Release of Security Interest in Trademarks

January 31, 2011

WHEREAS, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower, certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated as of May 11, 2010;

WHEREAS, pursuant to the GCA, Credit Suisse and King Pharmaceuticals Research and Development, Inc., a Delaware corporation (the “**Assignee**”), entered into that certain Trademark Security Agreement dated May 11, 2010 and recorded with the United States Patent and Trademark Office on May 13, 2010 on Reel No. 4205, Frame No. 0312 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (collectively, the “**Released Trademark Collateral**”);

WHEREAS, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and

WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.

[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH

By: 
Name: DOREEN BARR
Title: DIRECTOR

By: 
Name: VIPUL DHADDA
Title: ASSOCIATE

[signature page – King Pharmaceuticals Research and Development, Inc. trademark release]

Schedule 1

KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.

U.S. TRADEMARK REGISTRATIONS

Trademark	Registration No.	Registration Date
ADENOCARD	1473847	January 26, 1988
ADENOSCAN	1816335	January 11, 1994
ADENOSCAN	1541189	May 30, 1989
ALTACE	1812659	December 21, 1993
AVINZA	2669786	December 31, 2002
AVINZA (Design)	3319329	October 23, 2007
CORGARD	1040408	June 1, 1976
CORZIDE	1170890	September 29, 1981
CYTOMEL	2167335	June 23, 1998
DP	3049183	January 24, 2006
DP and Design	1742709	December 29, 1992
Enema Design	1810413	December 14, 1993
LEVOXYL	2016089	November 12, 1996
Levoxyl Tablet Design	2158841	May 19, 1998
LIQUI-CHAR	1657982	September 24, 1991
PULMONAIRE ¹	874778	August 12, 1969
REMOXY	3362798	January 1, 2008
SILVADENE	926416	January 4, 1972
SILVADENE	1020307	September 16, 1975
SKELAXIN	715343	May 16, 1961
SONATA	2168566	June 23, 1998
SYNERCID	1772760	May 25, 1993
SYNERCID and Design	2396275	October 17, 2000
THEREVAC	1652129	July 30, 1991
THROMBIN-JMI	2044605	March 11, 1997
THROMBI-PAD	3,550,781	December 23, 2008
TUSSIGON	1393762	May 20, 1986

U.S. TRADEMARK APPLICATIONS

Trademark	Application No.	Application Date
KING ON DEMAND	77/253473	August 13, 2007
OPTIMAL OPIOID PHARMACOTHERAPY IN INDIVIDUALIZED MULTIMODAL ANALGESIA & Design	85/057,044	June 8, 2010
PAINWATCH & Design	77,945,568	February 26, 2010

¹ Trademark registered in the name of Jones Medical Instrument Company (predecessor to KPR&D). The registration was renewed on behalf of Jones Medical Instrument Company in 2009.

Trademark	Application No.	Application Date
PAINWATCH & Design	77/945,569	February 26, 2010
REMOXY XRT and Design	77/612033	November 11, 2008
REMOXY XRT and Design	77/612057	November 11, 2008
THROMBI-PASTE	77/103099	February 8, 2007

TRADEMARK LICENSES

Name of Agreement	Parties Licensor/Licensee	Date of Agreement	Subject Matter
License, Development and Commercialization Agreement	Acura Pharmaceuticals, Inc./ King Pharmaceuticals Research and Development, Inc.	October 30, 2007	Acurox and follow-on products
Assignment, Assumption and Consent Agreement	Elan Pharma International Limited and Elan Management Limited/ King Pharmaceuticals Inc. and King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
Bill of Sale and Assignment and Assumption Agreement	Ligand Pharmaceuticals, Inc./ King Pharmaceuticals Research and Development, Inc.	February 26, 2007	Avinza
Asset Purchase Agreement	Allerex Laboratory Ltd., Anna Maria Solinas Laroche, Rita Fraser, 1055733 Ontario Limited/ King Pharmaceuticals Research and Development, Inc., and 6494871 Canada Ltd.	March 1, 2006	Epi-Pen
Amended and Restated Asset Purchase Agreement	Elan Corporation, plc, Elan Pharma International Limited, Elan Pharmaceuticals, Inc./ King Pharmaceuticals, Inc., Jonas Pharma Incorporated, and Monarch Pharmaceuticals, Inc.	May 19, 2003	Skelaxin